BioNTech SE (BioNTech) is a biotechnology company that develops immunotherapies for cancer and infectious diseases. It is investigating mRNA therapeutics, engineered cell and gene therapies, antibodies and small molecule immunomodulators to treat advanced melanoma, solid tumors, non-small cell lung cancer (NSCLC), prostate, head and neck, ovarian, pancreatic and triple negative breast cancer. The company is also evaluating treatments for HIV, tuberculosis, malaria, hepatitis B, influenza, and COVID-19. BioNTech uses FixVac and iNeST technology platforms to discover and develop cancer immunotherapies targeting antigens and neoantigens. It works in partnership with Genentech Inc, Pfizer, Genmab AS and other biopharmaceutical companies to develop its pipeline products. BioNTech is headquartered in Mainz, Rhineland-Palatinate, Germany.
Headquarters
Germany
Address
An Der Goldgrube 12, Mainz, Nordrhein-Westfalen, 55131
Website
www.biontech.com
Telephone
49 4961 3190840
No of Employees
6,133
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
BNTX (NASD)
Revenue (2022)
$4.1B
-77.9%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-90.1%
(2022 vs 2021)
Market Cap*
$20.6B
Net Profit Margin (2022)
XYZ
-55.3%
(2022 vs 2021)
* As of and is in US$
BioNTech SE premium industry data and analytics
Products and Services
| Products | Services |
|---|---|
| Marketed | - |
| BNT162 | Manufacturing Services |
| Pipeline | Diagnostics |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Plans/Strategy | In December, the company announced its plans to begin production at its mRNA vaccine factory in Rwanda by 2025. |
| 2023 | Contracts/Agreements | In November, the company entered into an agreement with Biotheus to create and market a bispecific antibody candidate targeting PD-L1 and VEGF in a variety of solid tumor indications. |
| 2023 | Acquisitions/Mergers/Takeovers | In November, the company acquired AexeRNA and its novel lipid nanoparticles for mRNA medicines. |
Competitor Comparison
| Key Parameters | BioNTech SE | Genmab AS | Curevac NV | Deutsche Biotech Innovativ AG | eTheRNA Immunotherapies NV |
|---|---|---|---|---|---|
| Headquarters | Germany | Denmark | Germany | Germany | Belgium |
| City | Mainz | Koebenhavn V | Tuebingen | Hennigsdorf | Antwerp |
| State/Province | Nordrhein-Westfalen | - | Baden-Wurttemberg | Berlin | Anvers |
| No. of Employees | 6,133 | 2,204 | 1,049 | - | 75 |
| Entity Type | Public | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Ugur Sahin, M.D. | Chief Executive Officer | Senior Management | 2008 | 58 |
| Jens Holstein | Chief Financial Officer | Senior Management | 2021 | 60 |
| Sierk Poetting | Chief Operating Officer | Senior Management | - | 50 |
| Ryan Richardson | Chief Strategy Officer | Senior Management | 2020 | 44 |
| James Ryan | Chief Legal Officer | Senior Management | 2023 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward